Title : Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center.

Pub. Date : 2019

PMID : 31696059






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 For patients with BBM receiving sequential therapy beyond the first disease progression after crizotinib treatment (1st PD), crizotinib beyond progressive disease (CBPD) plus local therapy can lead to a significantly longer PFS2 (67.0 vs. 21.0 weeks; p = 0.046). crizotinib GINS complex subunit 2 Homo sapiens